SEPNA

Septerna is a clinical-stage biotechnology company focused on discovering and developing oral small molecule medicines against G protein-coupled receptors (GPCRs). Its proprietary Native Complex Platform is designed to identify and optimize drug candidates for historically difficult-to-drug GPCR targets, enabling agonists, antagonists, and allosteric modulators across multiple receptor classes. The company’s lead wholly owned programs include SEP-631, an oral MRGPRX2 inhibitor for chronic spontaneous urticaria and other mast cell-driven diseases, a PTH1R agonist program for hypoparathyroidism, and a TSHR antagonist program for Graves' disease and thyroid eye disease. Septerna also has a major strategic collaboration with Novo Nordisk to develop oral small molecule therapies for obesity and other cardiometabolic diseases across multiple GPCR targets. The company is headquartered in South San Francisco and became publicly listed on Nasdaq in 2024.